An Alternative to Pharmaceutical Patents Christian Engström Vice Chairman, The Swedish Pirate Party.

Slides:



Advertisements
Similar presentations
Caribbean Central American Action (CCAA) Strengthening in the Third Border (CBI) CCA 27 th Annual Miami Conference on the Caribbean Basin Dr Rosanna Cooper,
Advertisements

1 Policy options to address access to chronic disease medicines Dr. Richard Laing Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
HR-676 Retirees dedicated to the passage of National Health Care (HR-676)
Access to Medicine Index 21 September 2010 Brussels, Wim Leereveld Journées Thématiques Médicament.
Benjamin Blasco Anna Ferretti Sophie Venet BIO615 Fall 2009.
The Medical Innovation Prize Fund S.2210, 110 th U.S. Congress David Reynolds, DrPH Senior Health Policy Advisor Senator Bernie Sanders
Patent linkage and the TPP Commercial considerations relevant to TPP 1 Geraldine Storton Hospira Pty Ltd.
Lecture 9 Tuesday, October 2 Healthcare and the Market.
Possible Impact of Market Exclusivity Extension on Pharmaceuticals in Thailand Chutima Akaleephan International Health Policy Program, Thailand 27 August.
The Great Depression.  What would happen if you spent more money that you actually had?  What happens when many people and businesses are in that situation?
The Global Generic Medications Market
Medicine Access: Claims & Data Sanjay Basu. The Framework for Access The pipeline fallacy Patents and pricing.
The Ohio State University GBM 9/8/2014 AMCP Managed Care 101.
Medication Use. Discussion Question #1 “Drugs represent one of the classical conundrums of life. We can’t live with them; we can’t live without them.”
The Global Pharmaceutical Industry Timothy F Christian, MD, MPA.
The Pharmaceutical Industry in Europe Key data INDUSTRY (EFPIA Total) (*) Production63,127121,311158,647170,000 (e) Exports23,18089,443144,022170,000.
More on Generic Drugs Global Classrooms 2013 Rachel Hunkler.
Policy Issues Concerning Parallel Trade of Pharmaceutical Drugs in the United States James Love CPTech FDA Prescription Drug Importation Meeting 14 April.
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
Health care system in Belgium How Belgian patients can save 1 billion euro / year and the health insurance system 1,6 billion / year …
© 2011 wheresjenny.com Healthcare : A Money Making Business Douris Hospital Once upon a time people became doctors and nurses because they wanted to help.
The Role of TNCs and AIDS drugs – “Lives before profits”? L.O.s 1.To define the terms: TNC, Generic, “Big Pharma”, ARVs, HAART, Tiered Pricing. 2.To describe.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
What You Want to Know About Generic Drugs Generic Drugs: Safe. Effective. FDA-Approved.
“Improved Medicare For All” for Beginners (Part A)
PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.
© 2010 Cengage Learning. All Rights Reserved. May not be scanned, copied or duplicated, or posted to a publicly accessible website, in whole or in part.
Restrictions on exports of medicine: irrational public policy, backdoor efforts to marginalize compulsory licensing, or Northern protectionism? James Love.
Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?
The competition between innovative and generic pharmaceutical companies intensified in the last decades. The models created by innovative pharmaceutical.
Healthcare SP-35 Michael Mahaney Tianna Nguyen Edward Poitras Matthew Pry.
Drug Prices in Canada and the US: More Than Meets the Eye? National Academy of Social Insurance Annual Conference Wayne Critchley Executive Director, PMPRB.
U.S. Drug Costs Dropped in 2012, but Rises Loom Katie Thomas The New York Times March 18, 2013
TBS Seminar on Essential Medicines and Health Products Geneva, 29 October 2013 Matthew Jowett, PhD Senior Health Financing Specialist Dept. Health Systems.
The Patient Protection and Affordable Care Act Our Healthcare Reform Law Why do we need it? What does it do for us?
3rd National Conference on medicines policy, Bratislava December 2006 Medicines Policy and equity in health How can generic drug producers contribute?
CBO ANALYSIS OF SAVINGS FROM PRESCRIPTION DRUG IMPORTATION Colin Baker Margaret Nowak Anna Cook June 8, 2004.
 The pharmaceutical industry develops, produces, and markets drugs or pharmaceuticals licensed for use as medications.  Pharmaceutical companies are.
A L ESSON IN H EALTH E CONOMICS C HAPTER 13 Code Blue Health Science Edition 4.
Market Failure What happens when the market doesn’t work?
Incentives for Innovation (Push and Pull) Andrew Alexandra Director Australian Research Council Special Research Centre for Applied Philosophy and Public.
Do Patents Make HIV/AIDS Medication Inaccessible to Patients in Sub-Saharan Africa? Abstract There has been debate surrounding the issue of patents and.
ANNOUNCEMENTS 1.New Chapter on Finance is available at 2.Updated chapters on Healthcare and the Environment also available at 3.All.
Gerald Friedman Professor of Economics
Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?
Objective The aim was to assess purchasing pharmaceuticals in the public health sector in Jordan through the joint procurement for participating parties.
Strictly confidential How to achieve sustainability in rapidly changing environment? Pavle Marjanović, Country Manager for Actavis Republic of Serbia and.
HSC 6636: Pharmaceuticals & Medical Technology 1 Dr. Lawrence West, Health Management and Informatics Department, University of Central Florida
Pharmaceuticals – a recap Discuss the view that “drugs companies are not fully addressing the needs of the world’s poorest people.”
Our PatientsOur PeopleOur BusinessOur Community © 2008 Endo Pharmaceuticals. All Rights Reserved. Biosimilars 2009 Update Pending Legislation Review Pam.
The Pharmaceutical Market Evolution Petru Crăciun ZF Pharma – Bucharest 2015, September 22 nd.
Protection of Intellectual Property in Canada George Jackowski, Ph.D., KCTJ October 19 th, 2015 Chairman of NAVA Corp.
Patents, Prizes, AMCs and CAMCs Aidan Hollis University of Calgary October 2007.
A Market for Vaccines Xavier Sala-i-Martin Columbia University November 2005.
ARRRR! Drug Development and Discovery Access to Essential Medicines De-Cal Fall Week 2.
The Case for a Free Market in Prescription Drugs Dean Baker, Co-director Center for Economic and Policy Research January 16, 2016.
March 2008 – DRAFT 1 Electronic Health Record (EHR) Task Force Financial Analysis Isabelle de Zegher and Greg Stadler.
A Market for Vaccines Xavier Sala-i-Martin. Recall AIDS Fund (AIDS Fund) Governments of Rich Countries contribute to a fund The money is spent to buy.
Positions of pharmaceutical companies Analysis of the websites of the three world’s largest PCs: Pfizer, Roche and Novartis.
Managed Care Lesson 2:4. Managed Care Plans Differ from one another in some respects, but are all designed to cut the cost of health care delivery. The.
Competition and Intellectual Property Protection in the Pharmaceutical Sector Alexey Ivanov Director, HSE-Skolkovo Institute for Law and Development Director,
Healthcare and the Market
Policy Options for Low and Middle Income Countries (LMIC)
Whole Washington Better healthcare for less
An Increasing Demand for Prescription Drugs Drives Profitability
On 1000-Fold Pharmaceutical Price Markups and Why Drugs Cost More in the United States than in Mexico  Leslie V. Boyer, MD  The American Journal of Medicine 
Healthcare and the Market
Providing Affordable Healthcare in an NHI environment
Commonalities across treatments and diseases: A brief overview
Drug Pricing, Innovation, and the Cycle of Greed
Presentation transcript:

An Alternative to Pharmaceutical Patents Christian Engström Vice Chairman, The Swedish Pirate Party

2 Pharmaceutical Patents Kill  Third world countries are prevented from manufacturing medicines they could afford  Costs for medicines are increasing in the rich world, and nobody has control  Research priorities get skewed - “me too” drugs instead of life saving new drugs

3 Paying for Drug Research  Who would pay for the R&D without patents?

4 Paying for Drug Research  Who pays for the R&D today?

5 Pharma Industry Figures “The Pharmaceutical Industry in Figures 2006” by EFPIA, European Federation of Pharmaceutical Industries and Associations

6 Pharmaceutical Reimbursement The Pharmaceutical Industry in Figures 2006, page 37

7 The Government Pays Today Individual patients 17% Governments 83% (Compulsory Health Insurance)

8 What Are The Costs?  Manufacturing the actual substances  Research & Development

9 Manufacturing - Generic Drugs  Patent free, no R&D costs  Generic drugs are cheap: 70-90% reduction  Swedish FDA reported 70% in a study

10 Generic Drugs Are Cheap  30% of today's cost is a conservative estimate that includes:  Manufacturing  Distribution  Administration  Marketing  Profit

11 What Are The Costs? Manufacturing etc.

12 How Much Is Spent on R&D ?  Specified in the annual reports:  Pfizer 2006: 15.7%  Novartis 2006: 14.8%  AstraZeneca 2006: 14.7%  Industry as a whole: 15%

13 What Are The Costs? Manufacturing etc. R&D

14 What Are The Costs? Manufacturing etc. R&D Patent monopoly cost

15 Without Patents We Could  Cut the government's pharma bill by 50%  Allow developing nations free access  Save money and save lives